A Clinical Multicenter Trial of Recombinant Human Interferon Gamma in Tuberculosis (GAM2022): Experience with the Use of Human Recombinant Interferon Gamma in TB Practice

Background In this article, we present the results of a multicenter clinical trial of IFN-γ in patients with drug-susceptible and drug-resistant pulmonary Tuberculosis (TB) in routine clinical practice. Objective This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB. Methods All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy. Results Recombinant human IFN-γ proved high efficacy in multi-center clinical trial in routine TB practice. Conclusion The results show that IFN-γ is efficient and safe in the treatment of pulmonary tuberculosis. Clinical Trial Registration #: NCT06118619.